Loading
Testing a patient's inherited genes before certain chemotherapies to spot people who cannot break the drug down and would suffer severe, sometimes fatal, side effects.
Germline variants alter how patients handle several cancer drugs. DPYD variants reduce dihydropyrimidine dehydrogenase and cause severe toxicity with fluorouracil and capecitabine; UGT1A1*28 raises irinotecan toxicity; TPMT and NUDT15 variants make thiopurines dangerous. Pre-treatment DPYD testing is required or recommended across much of Europe and by the NHS, and dose reduction guided by genotype has been shown to cut severe toxicity without loss of efficacy.
Genotype defined variants from blood or saliva and adjust starting doses according to consortium guidelines such as those of the Clinical Pharmacogenetics Implementation Consortium.
Query for this technology: (TITLE:"Pharmacogenomic testing before chemotherapy" OR ABSTRACT:"Pharmacogenomic testing before chemotherapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pharmacogenomic testing before chemotherapy, not a curated reading list.
Shares UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer.
Shares UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer.
Shares UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer.
Commercial and regulated products that serve this technology. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
The risk model behind familial breast and ovarian cancer clinics: it takes family history, genetic test results and risk factors and returns a personal risk over time.